查看完整行情页>>

|

货币单位:美元(USD)

Biocept, Inc. (bioc)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Robert Walsh Presently, Robert Walsh is Chief Accounting Officer, VP & Controller at Biocept, Inc. He previously held the position of Health Industries Assurance Practice at PricewaterhouseCoopers LLP. Mr. Walsh received an undergraduate degree from the University of Rhode Island.
Antonino Morales Currently, Antonino Morales holds the position of President, CEO, Chief Financial Officer & Director at Biocept, Inc. In the past he was President & Chief Executive Officer of Apoyo Financiero, Inc. He received an undergraduate degree from the University of Southern California.
Darrell Taylor Darrell Taylor holds the position of Chief Legal & Compliance Officer, Senior VP at Biocept, Inc. He previously held the position of Chief Compliance Officer for Precision Toxicology LLC. Mr. Taylor received a graduate degree from the University of Notre Dame The Law School.
Philippe Marchand Presently, Philippe Marchand holds the position of Chief Operating Officer of Biocept, Inc. In his past career he occupied the position of Chief Operating Officer at Biosplice Therapeutics, Inc. and Chief Information Officer at Genoptix, Inc. He received a doctorate and a graduate degree from L'Universite de Haute Alsace.
Nathaniel Sweed Nathaniel Sweed is Medical Director of Biocept, Inc. He received an undergraduate degree from the University of Houston, a doctorate from the University of Texas Health Science Center At San Antonio and a graduate degree from The University of Texas Southwestern Medical Center.
Barbara Blouw Barbara Blouw occupies the position of Vice President-Clinical Development at Biocept, Inc.
Linda M. Rubinstein Linda M. Rubinstein holds the position of Chief Financial & Accounting Officer at Adverum Biotechnologies, Inc. She is also on the board of Biocept, Inc. and Partner at FLG Partners LLC. Ms. Rubinstein previously occupied the position of Chief Financial Officer at RenovoRx, Inc., Chief Accounting Officer of Alector, Inc., Chief Financial Officer at Apexigen, Inc., Chief Financial & Accounting Officer at Five Prime Therapeutics, Inc., Chief Financial Officer & Senior Vice President for Ingenuity Systems, Inc., Chief Financial Officer & Executive Vice President of Emergent Travel Health, Inc., Chief Financial Officer at ArmaGen, Inc., Chief Financial Officer of Solexa, Inc., Chief Financial Officer of iPierian, Inc., Senior Banker at Lehman Brothers, Inc. and Principal at Merrill Lynch Capital Partners, Inc. Linda M. Rubinstein received an undergraduate degree and a graduate degree from the University of California, Los Angeles.
Bruce E. Gerhardt Currently, Bruce E. Gerhardt holds the position of Chairman of Biocept, Inc. He is also Member of The American Institute of Certified Public Accountants. In the past Mr. Gerhardt held the position of Senior Accountant at KPMG (Auckland). Mr. Gerhardt received an undergraduate degree from the University of Southern California.
Quyen Dao-Haddock Presently, Quyen Dao-Haddock occupies the position of Controller for IQHQ, Inc. She is also on the board of Biocept, Inc. In the past she occupied the position of Chief Accounting Officer for Presidio Property Trust, Inc., Controller at Pacific Corporate Group LLC and Audit Manager at KPMG LLP. She received an undergraduate degree from San Diego State University.
Marsha Alpert Chandler Marsha Alpert Chandler is on the board of Biocept, Inc., Corporate Directors Forum and Museum of Contemporary Arts San Diego and Senior Vice Chancellor-School of Global Policy at the University of California San Diego. Dr. Chandler previously was Chief Operating Officer & Executive Vice President of The Salk Institute for Biological Studies. Dr. Chandler received a doctorate from The University of North Carolina at Charlotte.
Ivor Royston Ivor Royston is an entrepreneur and businessperson who founded Hybritech, Inc., Forward Ventures Services LLC, IDEC Pharmaceuticals Corp. and IDEC Corp. (United States) and who has been at the head of 7 different companies. Presently, he occupies the position of President, Chief Executive Officer & Director at Viracta Subsidiary, Inc. Dr. Royston is also on the board of Viropro, Inc., Biocept, Inc., CONNECT and Viracta Therapeutics, Inc. (former President, Chief Executive Officer & Director). In the past Ivor Royston occupied the position of Director-Clinical Immunology at San Diego Cancer Center, Managing Member at Forward Ventures Services LLC, Director at Morphotek, Inc., Chairman for TargeGen, Inc., President, Chief Executive Officer & Director at Sunesis Pharmaceuticals, Inc., Director at LigoCyte Pharmaceuticals, Inc., President & Chief Executive Officer for Sidney Kimmel Cancer Center, Member of the University of California San Diego and Director-Clinical Immunology at the University of California. Dr. Royston received an undergraduate degree and a doctorate from The Johns Hopkins University.